Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Psoriasis triggered by infliximab in a patient with Behçet's disease.

Kawazoe Y, Sugita S, Yamada Y, Akino A, Miura K, Mochizuki M.

Jpn J Ophthalmol. 2013 Jan;57(1):95-7. doi: 10.1007/s10384-012-0198-4. Epub 2012 Oct 23.

PMID:
23090423
2.

Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.

Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A.

Arthritis Rheum. 2005 Aug;52(8):2513-8.

3.

Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.

Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P.

Jpn J Ophthalmol. 2007 May-Jun;51(3):191-6. Epub 2007 Jun 7.

PMID:
17554481
4.

The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.

Morris DS, Gavin MP, Sturrock RD.

Adv Exp Med Biol. 2003;528:557-9. No abstract available.

PMID:
12918763
5.

Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab.

Ju JH, Kwok SK, Seo SH, Yoon CH, Kim HY, Park SH.

Clin Rheumatol. 2007 Aug;26(8):1383-5. Epub 2006 Oct 13.

PMID:
17039261
6.

Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years.

Kanemaru H, Makino T, Jinnin M, Yonemitsu A, Makino K, Ihn H.

J Dermatol. 2013 Aug;40(8):632-4. doi: 10.1111/1346-8138.12203. Epub 2013 Jun 3.

PMID:
23724912
7.

Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.

Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA.

Rheumatology (Oxford). 2014 Dec;53(12):2223-31. doi: 10.1093/rheumatology/keu266. Epub 2014 Jul 4.

PMID:
24996907
8.

Infliximab-induced psoriasis during therapy for Crohn's disease.

Steinwurz F, Denadai R, Saad-Hossne R, Queiroz ML, Teixeira FV, Romiti R.

J Crohns Colitis. 2012 Jun;6(5):610-6. doi: 10.1016/j.crohns.2011.12.007. Epub 2012 Jan 26.

PMID:
22398095
9.

Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.

Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, Kaburaki T, Maruyama K, Nakai K, Hijioka K, Shibuya E, Komae K, Hori J, Ohguro N, Sonoda KH, Mizuki N, Okada AA, Ishibashi T, Goto H, Mochizuki M.

Ophthalmology. 2014 Oct;121(10):1877-84. doi: 10.1016/j.ophtha.2014.04.042. Epub 2014 Jun 18.

PMID:
24950593
10.

Anti-TNF-alpha therapy for sight threatening uveitis.

Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM.

Br J Ophthalmol. 2005 May;89(5):533-6.

11.

Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report.

Li Y, Han Z, Wang X, Mo Z, Zhang W, Li A, Liu S.

BMC Gastroenterol. 2013 Dec 9;13:167. doi: 10.1186/1471-230X-13-167.

12.

Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders.

Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM.

Swiss Med Wkly. 2002 Jul 27;132(29-30):414-22.

PMID:
12428187
13.

Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy.

Kawaguchi T, Kawazoe Y, Kamoi K, Miyanaga M, Takase H, Sugita S, Mochizuki M.

Jpn J Ophthalmol. 2014 Jan;58(1):75-80. doi: 10.1007/s10384-013-0283-3. Epub 2013 Oct 16.

PMID:
24129677
14.

Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature.

Almoznino G, Ben-Chetrit E.

Clin Exp Rheumatol. 2007 Jul-Aug;25(4 Suppl 45):S99-102. Review.

PMID:
17949561
15.

[Infliximab treatment trial in a patient with neuro-Behçet's disease unresponsive to other treatments].

Kadowaki S, Matsuda N, Moriya A, Ebitani M, Yoshihara A, Nakamura K, Mochizuki H, Ugawa Y.

Rinsho Shinkeigaku. 2011 Apr;51(4):261-6. Japanese.

PMID:
21595295
16.

Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.

Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M.

Arthritis Res Ther. 2012 May 1;14(3):R99. doi: 10.1186/ar3824.

17.

Induction of regulatory T cells by infliximab in Behcet's disease.

Sugita S, Yamada Y, Kaneko S, Horie S, Mochizuki M.

Invest Ophthalmol Vis Sci. 2011 Jan 21;52(1):476-84. doi: 10.1167/iovs.10-5916.

PMID:
20861484
18.

Mimicry between intestinal Behçet's disease and inflammatory bowel disease.

Rodrigues-Pinto E, Magro F, Pimenta S, Guimarães J, Macedo G.

J Crohns Colitis. 2014 Jul;8(7):714-5. doi: 10.1016/j.crohns.2013.12.009. Epub 2014 Jan 2. No abstract available.

PMID:
24389388
19.

Adalimumab for sight-threatening uveitis in Behçet's disease.

Mushtaq B, Saeed T, Situnayake RD, Murray PI.

Eye (Lond). 2007 Jun;21(6):824-5. Epub 2006 Apr 7.

PMID:
16601736
20.

Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case.

Kram MT, May LD, Goodman S, Molinas S.

Dis Colon Rectum. 2003 Jan;46(1):118-21.

PMID:
12544532

Supplemental Content

Support Center